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Abstract
Combination therapy with anticholinergics and b2-agonists should be used in COPD patients after failure of previous monothe-
rapy with one of these drugs. Synergistic effect of both mechanisms of bronchodilation can maximize the efficacy of separately 
administered drugs. The effectiveness of the combination of LABA and LAMA is already confirmed, nevertheless the question 
about the safety profile of this therapy is still remaining, particularly with regard to the cardiovascular system. The paper discus-
ses the overall safety profile of the combined preparation compare to placebo as well as the active comparators, especially the 
cardiovascular safety of fixed-dose formulation. Based on the data it has been demonstrated, that the combination of two ultra
-long-acting bronchodilators with different complementary mechanisms of action increases the effectiveness of COPD therapy 
without affecting the safety.
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Streszczenie
Skojarzone leczenie b2-mimetykami z cholinolitykami powinno być zastosowane u chorych na przewlekłą obturacyjną chorobę 
płuc (POChP) w przypadku braku złagodzenia objawów przy podaniu jednego z tych leków. Działanie poprzez dwa mechanizmy 
rozszerzania oskrzeli może bowiem zmaksymalizować efekt bronchodylatacyjny. Potwierdzona skuteczność terapii skojarzonej 
LABA i LAMA wywołuje pytanie o jej profil bezpieczeństwa, zwłaszcza w odniesieniu do wpływu na układ sercowo-naczyniowy. 
W pracy omówiono ogólny profil bezpieczeństwa stosowania tego skojarzonego preparatu, profil bezpieczeństwa w stosunku do 
placebo, a także w stosunku do aktywnych komparatorów. Szczegółowej analizie poddano profil bezpieczeństwa sercowo-naczy-
niowego tego dwuskładnikowego preparatu. Na podstawie zgromadzonych danych wykazano, że połączenie tych dwóch ultra-
długodziałających leków rozszerzających oskrzela o różnych, uzupełniających się mechanizmach działania zwiększa skuteczność 
terapii POChP, nie wpływając jednocześnie na spadek jej bezpieczeństwa.
Słowa kluczowe: leczenie skojarzone, indakaterol, glikopironium, układ sercowo-naczyniowy
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Introduction
As it was presented in Global Initiative for 
Chronic Obstructive Lung Disease (GOLD 2014) 
strategy, the combination therapy with anticho-
linergics and b2-agonists could be considered in 
COPD patients after failure of previous monother-
apy with one of these drugs [1]. The combination 
of LABA (long-acting beta 2-agonist) and LAMA 
(long-acting muscarinic agonist) is very often 
suggested as an alternative therapy for patients 
in group B, C and D. Compare to the dose in-
creasing during monotherapy, the combination 
of the bronchodilating drugs from two different 
classes could improve the effectiveness as well as 
decrease the risk of side-effects [2]. Additionally, 
two different mechanisms of bronchodilation can 
maximize this effect and equalize the diurnal 
variation in the intensity of symptoms, resulting 
from the higher daily activity of sympathetic 
system in contrary to the nocturnal activity of 
parasympathetic system. The 24-hour activity of 
the drug provides the effect of “pharmacological 
stent” of bronchial tree, leading to reducing of 
hyperinflation and subsequent alleviation of 
dyspnea, which is the most worrisome symptom 
reported by COPD patients.
The effectiveness of the combination of LABA 
and LAMA is already confirmed, nevertheless the 
question about the safety profile of this therapy 
is still remaining, particularly with regard to 
the cardiovascular system. The effects of action 
of beta-adrenoreceptor agonists (b-agonists) is 
relaxation of bronchial smooth muscle and in 
heart — increasing of sinus rhythm frequency 
(positive chronotropic effect), increasing of con-
duction velocity in atrioventricular (AV) node 
(positive dromotropic effect) and increasing of 
contraction strength of the myocardium (positive 
inotropic effect). The influence of b2-mimetics on 
glucose and potassium serum concentrations is 
also observed [3], and hypokalemia additionally 
exacerbates proarythmogenic effect. On the other 
hand, muscarinic receptor agonists decrease the 
cholinergic system tension therefore could cause 
tachycardia [4]. Whilst the dose of anticholiner-
gics increases, the inhibition of M2 receptors’ 
stimulation in AV node could potentiate this 
effect [5]. There are some reports in literature 
about increasing risk of myocardial infarctions 
in patients treated with LAMA [6]. 
It has been observed, that combination treat-
ment with LABA (salmeterole or formoterole) [7] 
with LAMA (tiotropium) [6] increased the heart 
rate as well as elicited other cardiovascular symp-
toms. Nevertheless, the clinical trials’ results did 
not indicate the risk of higher frequency or inten-
sity of side-effects during combination therapy 
with tiotropium (administered once daily) and 
formoterole (1 or 2 times per day) compare with 
monotherapy with those drugs [8, 9]. There are 
limited data about safety profile of combination 
therapy with salmeterole and tiotropium [10].
QVA149 in the novel fixed-dose combina-
tion of indacaterol (LABA) and glycopyrronium 
(LAMA), with unknown safety profile, especially 
in reference to cardiovascular system. The effec-
tiveness of both monocomponents, indacater-
ol (ultra-LABA) [11−15] and glycopyrronium 
(LAMA) [16, 17] has been previously confirmed 
in number of clinical trials, as well as their safety 
profile including cardiovascular action. 
This is all the more significant, because the 
patients with COPD are usually in old age, with 
many comorbidities, very often involving the 
cardiovascular system [18].
General safety profile
The clinical trial IGNITE indicated, that 
this fixed-dose combination is characterized by 
favorable safety profile and tolerance, and total 
side-effects frequency was similar to placebo and 
active control groups [19]. 
In general this combined preparation was 
well tolerated in patients with moderate-to-severe 
COPD and majority of adverse events were of 
mild and moderate intensity. No deaths related 
to the therapy have been noted [20−24]. Based 
on metaanalysis it has been revealed, that one 
third of 1076 patients treating with this fixed-dose 
combination had at least 3 cardiovascular risk fac-
tors [25]. The frequency of severe cardiovascular 
side-effects in patients treated with combination 
therapy (1.8%) was similar to the tiotropium 
group (1.7%), but lower than in patient treating 
with other comparators (indacaterol, glycopyrro-
nium, SFC: 2.3−3%) or placebo (2.6%). Angina 
pectoris, atrial fibrillation and ventricular and 
supraventricular extrasystoles were noted in 3 
(0.3%), 3 (0.3%), 3 (0.3%) and 2 (0.2%) patients 
treated with QVA149 (a pre-marketing name for 
indacaterol/glycopyrronium fixed dose combi-
nation as of 8th  July 2014), respectively [25]. 
The frequency of atrial fibrillation (both the first 
episodes and recurrent) was 0.8% in group treated 
with QVA149 and it was similar to the placebo 
group (0.6%), but lower as compare with patients 
treated with indacaterol (1.5%), glycopyrronium 
(2.1%), tiotropium (1.3%) and SFC (2.7%). The 
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changes of QTc length in ECG examination were 
noted in 1 patient taking QVA149. 1 in placebo 
group (in both cases it was QT prolongation) and 
in 2 patients treated with indacaterol (ventricular 
tachycardia) [25].
In  general the fixed-dose combination of 
indacaterol/glycopyrronium (IND/GLY) was also 
well tolerated by patients with severe-to-very 
severe COPD with high risk of exacerbations [26]. 
The frequencies of particular cardiovascular ab-
normalities, such as: atrial fibrillation, myocardial 
infarction, cardiac arrest and heart failure were 
similar (≤ 1%) to the groups taking glycopyrroni-
um and tiotropium [26].
Safety profile of fixed-dose combination 
indacaterol/glycopyrronium versus placebo
General safety profile as well as profile of 
cardiovascular and cerebrovascular side-effects of 
QVA149 was similar to the placebo, both during 
6 and 12 months observation in patients with 
moderate-to-severe COPD [22, 23]. 
In 26-weeks clinical trial SHINE the fre-
quency of serious cardiovascular side-effects was 
comparable in group treated with IND/GLY and 
taking placebo (0% in IND/GLY group vs. n =1, 
0.4% in placebo group). Paroxysmal atrial fibrilla-
tion and atrial flutter  were diagnosed in 2 (0.4%) 
patients treated with IND/GLY but in none in the 
placebo group. There were no clinically important 
differences between both groups regarding QTcF 
interval in ECG recording [23].
In 52-weeks clinical trial, investigating the 
safety of combination therapy with IND/GLY 
(ENLIGHTEN [22]), the cardiovascular and cere-
brovascular (CCV) side-effects were reported in 
active treatment as well as placebo group in 5.3% 
and 2.7% patients, respectively. The severe CCV 
were confirmed in 5 patients taking IND/GLY (two 
patients had major adverse cardiovascular events 
[MACE] deemed as connected with the progres-
sion of previously existing disease; none of that 
events were noted in  the placebo group). Ratio 
of MACE incidences per 100 patient-years was 
1.0 in the group treated with IND/GLY and 0 in 
group taking placebo, and difference in frequency 
of CCV serious adverse event (SAE) between both 
groups did not reach statistical significance (odds 
ratio [OR] 3.25; p = 0.284). 
Based on network metaanalysis including 
1547 patients treated with combination therapy 
and 2141 taking placebo it has not been indicated 
the increased risk of death (hazard ratio, [HR] 
0.922, 95% confidence interval [CI] 0.338, 2.511), 
severe CCV events (HR 0.597, 95% CI 0.287, 
1.241), MACE (HR 0.984, 95% CI 0.417, 2.319) or 
atrial fibrillation/flutter episodes (HR 1.017, 95% 
CI 0.479, 2.157) [27]. 
Side-effects of fixed-dose combination 
indacaterol/glycopyrronium versus active 
comparators
Side-effects profile of the fixed-dose combi-
nation was similar to the safety profiles of active 
comparators: monocomponents — IND/GLY, used 
separately or combined, as well as tiotropium and 
combination of salmeterol and fluticasone [21, 
22, 24−26, 28].
In 4-weeks clinical trial BEACON, comparing 
efficacy and safety of fixed-dose combination IND/
GLY with relevant monocomponents (IND and 
GLY) there were no CCV SAE reported in any of 
the groups [28].
Similarly, in SPARK clinical trial, involving 
patients with severe and very severe COPD, there 
was no increasing number of side-effects, includ-
ing MACE in  patients treated with fixed-dose 
combination IND/GLY compare with glycopyrro-
nium and tiotropium [26]. Serious adverse events, 
cardiovascular serious adverse events and MACE 
were noted in 23, 3.7 and 1.4% patients treated 
with combination therapy, 24, 3.4 and 2.0% pa-
tients treated with glycopyrronium and 22, 3.5 
and 1.1% patients taking tiotropium, respectively.
In 26-weeks clinical trial assessing efficacy and 
safety of combination therapy (SHINE) [23] there 
were not reported serious CCV events in actively 
treated group as compare with isolated cases in the 
groups treated with indacaterol, glycopyrronium or 
tiotropium. Furthermore, there were no clinically 
important differences between the groups accord-
ing to QTc interval (Fridericia’s formula).
In 26-weeks clinical trial ILLUMINATE the 
frequency of cardiovascular abnormalities lead-
ing to treatment interruption was the same (0.8%) 
in the group of patients treated with fixed-dose 
combination IND/GLY and taking combination 
of salmeterole and fluticasone (SFC 50/500 mcg). 
One patient in SFC group died during trial, and 
a sudden cardiovascular death was recognized 
as a cause [21]. There were no new safety sig-
nals in metaanalyses involving patients with 
moderate-to-severe COPD treated with fixed-
dose combination IND/GLY as compare with 
active comparators: indacaterol, glycopyrronium, 
tiotropium and salmeterole/fluticasone [24]. The 
frequency of adverse events and serious adverse 
events including progression of COPD were 
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similar or even lower in patients treated with 
fixed-dose combination IND/GLY as compared 
with active comparators [24]. Additionally, 
no increased risk of CCV was observed in this 
group. The frequency of CCV, including SAE (also 
MACE) and atrial fibrillation/flutter episodes in 
patients treated with combination therapy IND/
GLY was similar or numerally lower versus active 
comparators [24, 25].
Cardiovascular safety profile of fixed-dose 
combination indacaterol/glycopyrronium
As the results of the searching of PubMed 
literature database (using search terms: „QVA149 
+ cardiac safety”, „QVA149+ cardiovascular”, 
„QVA149+potassium” 4 publications describing 
QVA149 cardiovascular safety profile, of which 
2 were rejected due to secondary character or 
lack of direct relevance with treatment of that 
preparation. One of those trials involved healthy 
volunteers [29], and the second one patients with 
moderate-to-severe COPD [30].
The first trial it was randomized, dou-
ble-blinded study, assessing effect of fixed-dose 
combination on cardiovascular parameters and 
glucose and potassium serum concentration in 50 
healthy volunteers compare to placebo [29]. Sim-
ilar analyses were performed versus indacaterol 
600 μg, glycopyrronium 200 μg and salmeterole 
200 μg. Although the doses of the combination 
therapy exceeded 4-fold the therapeutic doses 
(indacaterol 440 μg and glycopyrronium 200 
μg), no clinically important effect on cardiovas-
cular parameters e.g. heart rate or QTcF interval 
prolongation in ECG was indicated. The biggest 
change of heart rate at some time point was 5.69 
beats per minute (90% CI: 2.71; 8.66). Slight de-
creasing of heart rate was observed in the group 
of patients treated with fixed-dose combination 
as compare to indacaterol and salmeterole, but 
little increasing (by 1.78 beats per minute) versus 
glycopyrronium (Fig. 1). Similarly, there was no 
important effect on the length of QTcF interval in 
ECG recording comparing to other active thera-
pies. Changing of potassium serum concentration 
compare to placebo and glycopyrronium was 
small. During both therapies the biggest changes 
of potassium serum concentration were observed 
4 hours 10 minutes after dose administration by 
–0.14 mmol/l (90% CI: –0.26, –0.01) and –0.12 
mmol/l (90% CI: –0.25, 0.01), respectively. In the 
majority of time points the changes of potassium 
serum concentration in patients treated with 
combination therapy were smaller than in patient 
taking salmeterole, and the biggest difference was 
0.21 mmol/l (90% CI: 0.08, 0.34 mmol/l) at 2 hours 
10 minutes after dose administration. The biggest 
differences in glucose serum concentration in the 
group of patients treated with QVA149 compare 
to placebo and glycopyrronium were 0.67 mmol/l 
(90% CI: 0.30, 1.03) and 1.13 mmol/l (90% CI: 
0.77, 1.49) at 8 hours 10 minutes and at 6 hours 
10 minutes after dose administration, respective-
ly. Comparing to indacaterol the differences of 
glycaemia were smaller, with the maximum of 
–0.18 mmol/l (90% CI: –0.54, 0.18) at 6 hours 10 
minutes after dose administration. The biggest 
difference was observed comparing to salmeterole 
e.g. –1.19 mmol/l (90% CI: –1.56, –0.82) at 6 hours 
10 minutes after dose administration.
The safety profiles of all analyzed therapies 
were similar, no serious adverse events and 
deaths were reported. The majority of adverse 
events were of mild intensity, the only moderate 
adverse event was the headache in one patients 
treated with fixed-dose combination of indacater-
ol and glycopyrronium. The authors concluded, 
that combination therapy did not induce tachy-
cardia comparing to indacaterol and glycopyrro-
nium alone and did not influence QTcF interval in 
Figure 1. Mean changes in heart rate compared with the baseline for 
24h; bpm — beats per minute
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healthy volunteers. As compared to salmeterole, 
effect on heart rate and QTcF interval was smaller. 
No clinically important changes of potassium and 
glucose serum concentrations were noted. In gen-
eral, the combination therapy was well tolerated.
Double-blinded, placebo-controlled clinical 
trial with parallel groups assessed cardiovascular 
safety of subtherapeutic doses of combination ther-
apy (600/100 μg, 300/100 μg or 150/100 μg) and in-
dacaterol alone in therapeutic dose of 300 μg versus 
placebo in 257 patients with moderate-to-severe 
COPD. The endpoints included effects on 24-hours 
heart rate measured in Day 14 [30] and change of 
baseline mean daily heart rate in Day 1 and 14, as 
well as changes of QTcF interval in ECG recording 
(Fridericia’s formula) in Day 14. No statistically sig-
nificant changes of mean daily heart rate were ob-
served in any of the patients treated with different 
doses of combination therapy and indacaterol alone 
300 μg. For 98.3% of differences versus placebo CIs 
ranged from −5 to +5 beats per minute. Similar 
analyses in Day 1 revealed, that mean daily heart 
rate in all therapeutic arms tended to decrease, 
with the biggest change of baseline values in pa-
tients treated with QVA149 600/100 μg (least mean 
squares −2.877 beats per minute as compare with 
−2.770, −0.547, −1.849, and −0.329 beats per 
minutes for QVA149 300/100 μg, QVA149 150/100 
μg, indacaterol 300 μg, and placebo, respectively. 
The differences for two highest doses of QVA149 
versus placebo were very close, but did not reach 
the statistical significance (p = 0.05).
No cases of ventricular tachycardia, ven-
tricular fibrillation/flutter or torsades de pointes 
were observed. In the group of patients treated 
with the dose of combination therapy of 150/100 
μg, with the more frequent baseline sporadic 
tachycardia (14.3%) and arrhythmias, no tenden-
cy neither to increasing or decreasing of those 
changes nor differences between therapeutic 
groups were noted. There were few episodes of 
atrial flutter, but the mean values in all analyzed 
groups, as well as during all study were zero. The 
frequency of short-lasting episodes of nonfixed 
supraventricular tachycardia was the highest in 
the group treated with QVA149 150/100 μg, but 
percentage value recovered to the baseline in 
Day 14. No differences of these episodes changes 
were noted in any of the therapeutic groups; the 
supraventricular arrhythmias slightly changed 
between the groups.
QTc intervals were similar in all time points 
(normal value < 470 ms in women and < 450 
ms in men). No clinically important differences 
in mean QTc intervals (Fridericia’s formula) be-
tween groups were noted. Visible changes of QTc 
interval were most frequent in group of patients 
treated with fixed-dose combination 600/100 μg 
(12.2%) as compare to lower doses of 300/100 
μg (7.8%) and 150/100 μg (2.0%); no changes of 
baseline values did not exceeded the threshold > 
60 ms. In any woman QTc interval did not reach 
the value >470 ms, and maximum prolongation 
of baseline QTc interval was below 30 ms using 
Fridericia’s formula. According to LS of QTc 
interval the differences between groups were 
minimal and no relations with administered dose 
was observed.
The tendency to shortening of baseline QTc 
interval (< 10 ms) was observed in all but in-
dacaterol/glycopyrronium 150/100 therapeutic 
groups. In this group the prolongation of QTc 
interval was noted in Day 7 and 14, nevertheless 
the values before dose administration were lower 
than baseline, and changes after taking a dose 
were small. 
In general the frequency of clinical symptoms 
was similar in all therapeutic groups. There was 
a tendency to decreasing of heart rate and blood 
pressure (both diastolic and systolic) after dose 
administration, without clinical importance. In 
all groups with active treatment the decreasing of 
heart rate after dose inhalation was noted in Day 
1, 7 and 14 with mean values ranged from 1.0 to 
5.0 beats per minute. The mean change was bigger 
in patients treated with QVA149 as compare to 
indacaterol alone 300μg, although no relations 
between dose and response were noted.
In all investigated groups the changes from 
baseline values of  mean sitting diastolic blood 
pressure (msDBP) decreased. Decreasing of 
msDBP values in Day 1, 7, and 14 was detect-
able, but did not exceed 4 mm Hg, what was of 
no clinical importance.
Majority of side-effects were of mild and 
moderate intensity. No relationship between 
dose of combination therapy and frequency of 
side-effects was noted. Serious adverse events 
were reported in 5 (2%) patients, leading in 3 
(1.2%) of them to dose interruption. The following 
adverse events were deemed as related to study 
drug administration: ventricular tachycardia (n = 
1 [2.0%]; combination therapy 150/100 μg), atrial 
fibrillation (n = 1 [2.0%]; combination therapy 
600/100 μg) and hyperkalemia (n = 1 [2.0%]; 
combination therapy 600/100 μg). Mentioned car-
diovascular events were revealed based on Holter 
ECG recording, but without clinical symptoms. 
Serious adverse events not related to the study 
drug included: anemia (n = 1 [2.0%]; combination 
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therapy 150/100 μg) and COPD exacerbation (n = 
1 [1.9%]; placebo). 
Summary
Combination of two bronchodilating drugs of 
different, complementary mechanisms of action 
improve the efficacy of COPD treatment, without 
reducing of safety. Combined preparation of inda-
caterol and glycopyrronium (Ultibro Breezhaler 
110/50 μg) is a fixed-dose combination of LABA 
and LAMA, administered once daily, with ad-
ditional therapeutic benefits for COPD patients 
and favorable safety profile. Efficacy of that drug 
was confirmed in many clinical trials based on 
spirometric parameters as well as clinical symp-
toms, especially dyspnea, general state of health, 
exercise tolerance, COPD exacerbation rate and 
usage of rescue medications.
The long-lasting, 24-hours bronchodilating 
effect of the drug provides „pharmacologic stent” 
for airways, leading to reducing of hyperinflation 
and subsequently to alleviating dyspnea. Addi-
tionally, it has beneficial influence on cardio-
vascular system. Hyperinflation decreases blood 
volume in chest and causes  insufficient left 
ventricular filling. It has been noted, that IC/TLC 
(inspiratory capacity to total lung capacity ratio, 
index of lung hyperinflation) < 0,25 leads to 
disturbances of left ventricular diastolic filling 
[31]. It was additionally confirmed, that this 
measure correlates with left ventricle end-dia-
stolic dimension (LVEDD). Diastolic dysfunction 
of left ventricle is independent factor affecting 
exercise tolerance in COPD patients. No clinical 
trials were identified directly investigating the 
influence of bronchodilating therapy on car-
diovascular parameters as follow: ventricular 
dimension, ejection fraction (EF) and parameters 
of left ventricular filling. It could be assumed, 
that decreasing of hyperinflation (based on IC 
measurement) by using combination therapy with 
ultra-long acting drugs e.g. indacaterol and glyco-
pyrronium (BRIGHT study [32]) should translate 
into improvement of circulation parameters and 
subsequent improvement of exercise tolerance. 
It is already proved, that bronchodilating drugs, 
together with lung volume reduction surgery 
(LVRSD) and pulmonary rehabilitation contribute 
to improvement of cardiovascular hemodynamic 
parameters [33].
Combination of two drugs in one capsule 
confirmed also the favorable safety profile, in-
cluding cardiovascular safety both in healthy 
volunteers and patients with COPD. Once daily 
administration improve patients’ adherence, 
leading to improved treatment efficacy. Accord-
ing to described features, presented fixed-dose 
combination is a valuable therapeutic option for 
patients on different stages of COPD.
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